Pegvisomant

Pegvisomant (B2036-PEG; trade name Somavert; CAS 218620-50-9) is a PEGylated recombinant human growth hormone (hGH) analogue engineered to function as a selective competitive antagonist of the growth hormone receptor (GHR), approved by the United States Food and Drug Administration in 2003 for the treatment of acromegaly in patients who have had an inadequate response to surgery, radiation therapy, or other medical therapies, or for whom these therapies are not appropriate. The compound consists of a 191-amino-acid polypeptide backbone (designated B2036) carrying nine amino acid substitutions relative to wild-type hGH: eight substitutions in the site 1 binding interface (His18Asp, His21Asn, Arg167Asn, Lys168Ala, Asp171Ser, Lys172Arg, Glu174Ser, Ile179Thr) that increase binding affinity for the first GHR molecule, and one substitution in the site 2 binding interface (Gly120Lys) that introduces a bulky lysine side chain preventing the conformational change required for functional receptor dimerization and activation of the JAK2-STAT5 signaling cascade [1, 2]. The B2036 protein is covalently conjugated with four to six polyethylene glycol (PEG) polymers of approximately 5 kDa each at lysine residues and the N-terminus, yielding a final molecular mass of approximately 42 to 52 kDa depending on PEGylation stoichiometry. PEGylation extends the plasma elimination half-life from approximately 15 minutes (unpegylated B2036) to 60 to 138 hours, reduces immunogenicity, and permits once-daily subcutaneous dosing [3, 4]. Pegvisomant was discovered in 1987 by John Kopchick and Wen Chen at the Edison Biotechnology Institute at Ohio University through transgenic mouse studies demonstrating that substitution of glycine 120 in the third alpha-helix of growth hormone with bulky amino acids abolished growth-promoting activity and created a functional antagonist of endogenous growth hormone action [1]. Sensus Drug Development Corporation licensed the technology and advanced the compound through clinical development with PEGylation applied to extend the pharmacokinetic profile. Pharmacia Corporation acquired Sensus in 2001 and was subsequently acquired by Pfizer. The FDA approved pegvisomant (Somavert) on March 26, 2003; the European Medicines Agency granted marketing authorization in November 2002 [5]. The mechanism of action is fundamentally distinct from the other medical therapies for acromegaly. Somatostatin receptor ligands (octreotide, lanreotide, pasireotide) and dopamine agonists (cabergoline) act at the pituitary level to suppress growth hormone secretion. Pegvisomant acts at the peripheral target organ level by competitively blocking GHR activation, thereby reducing hepatic production of insulin-like growth factor I (IGF-I), the principal mediator of the somatic and metabolic consequences of growth hormone excess. This peripheral mechanism renders pegvisomant effective regardless of pituitary tumor somatostatin receptor expression, GH secretory dynamics, or tumor histological subtype [2, 6]. In the pivotal Phase 3 randomized, double-blind, placebo-controlled trial reported by Trainer et al. (2000) in the New England Journal of Medicine, pegvisomant at 10, 15, and 20 mg daily subcutaneously for 12 weeks normalized serum IGF-I concentrations in 54, 81, and 89 percent of patients with acromegaly, respectively, compared to 10 percent on placebo [6]. Long-term surveillance data from the ACROSTUDY international observational registry, encompassing 2,221 patients followed for a median of 7.4 years, confirmed a favorable safety profile with IGF-I normalization rates reaching 75.4 percent at 10 years of treatment, pituitary tumor size increase in 7.1 percent by local reading, liver function abnormalities in 3.2 percent, and treatment-related adverse events leading to drug withdrawal in only 1.3 percent [7, 8]. Pharmacokinetics are characterized by slow subcutaneous absorption (time to peak concentration 33 to 77 hours), limited volume of distribution (approximately 7 liters), low renal clearance (less than 1 percent excreted unchanged in urine), and a long elimination half-life of 60 to 138 hours supporting once-daily dosing [3]. Bioavailability after subcutaneous injection is approximately 57 percent relative to intravenous administration. The compound does not cross the blood-brain barrier [9]. Approximately 17 percent of treated patients develop low-titer, non-neutralizing anti-growth hormone antibodies without apparent impact on efficacy [3]. The compound improves glucose metabolism and insulin sensitivity in acromegaly patients, an advantage over somatostatin analogues that may suppress insulin secretion and worsen glucose homeostasis [10, 11]. This monograph reviews the protein engineering, PEGylation chemistry, and structural pharmacology of pegvisomant; the molecular mechanism of growth hormone receptor antagonism; the comprehensive human pharmacokinetic record; preclinical pharmacology in transgenic and xenograft models; the clinical evidence base across the pivotal registration trial, long-term observational studies, and combination therapy investigations; sourcing and quality verification; reconstitution and handling; stack interactions with somatostatin receptor ligands, dopamine agonists, insulin, and other endocrine agents; the adverse-event and safety signal; and a structured comparative assessment of five alternative acromegaly pharmacotherapies (octreotide, lanreotide, pasireotide, cabergoline, and paltusotine) against pegvisomant on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).